Podcasts about Squamous cell carcinoma

Lisa Manyon was diagnosed in 2017 with Squamous Cell Carcinoma at the base of her tongue. Two years prior to receiving her diagnosis, she received a divine appointment to write a book about healing with love. Lisa journaled about it, tucked it away, and had no idea why she would be given such an assignment. In 2017 Lisa was reminded of this as she navigated facing mortality, including a misdiagnosis that she refused to accept. She intuitively knew something BIG was going on and she pushed for the answers she needed to heal with love and become a cancer thriver. Lisa has been NED since 2017. Lisa is the author of Spiritual Sugar: The Divine Ingredients to Heal Yourself With Love Order your copy of Lisa's book, Spiritual Sugar at https://spiritualsugar.com For speaking and consulting inquiries for Lisa, visit WriteOnCreative.com ____________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-epidsode Docuseries visit Hay House Online Learning. Click Here, to learn more about health coaching with Liz or Karla.   Follow us on Social Media: Facebook , Instagram, YouTube. ___________________ Thank you to our friends from The Healing Oasis for sponsoring this episode of the podcast.  The Healing Oasis is a first of its kind in beautiful British Columbia, Canada where we encourage the body to heal from cancer using alternative therapies & cancer fighting meals at a wellness retreat center in nature. Our top naturopathic cancer doctor will prescribe a protocol tailored specifically for you. There's no place quite like it. Start your healing journey today! Learn More about The Healing Oasis by visiting these links: Website   Testimonials Video Overview  

Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

Interview with Kathryn T. Shahwan, MD, author of Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma: Expert Panel Guidelines from ITSCC. Hosted by Adewole S. Adamson, MD, MPP. Related Content: Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma

Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42. ©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.US-NONO-00581 05/2024

Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42. ©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.US-NONO-00581 05/2024

Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br Dent J. 2022;233(9):780-786. Barsouk A, et al. Med Sci (Basel). 2023;11(2):42. ©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.US-NONO-00581 05/2024

Comprehensive, relevant and insightful conversations about health and medicine from the largest healthcare system in the Maryland D.C. region: this is MedStar Health DocTalk.In our latest podcast episode, host Debra Schindler talks with thoracic surgeon Dr. Duane Monteith and gastroenterologist Dr. Dana Sloan for a comprehensive look into esophageal cancer. They discuss everything from early symptoms and risk factors to advanced treatment options like minimally invasive surgery. This episode is packed with valuable insights that could make a significant difference in early detection and treatment. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s.  Our Guest:Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, Nova Scotia. He is currently a Professor of Surgery at Dalhousie University. His expertise and clinical interest includes rhinoplasty/nasal surgery, eyelid surgery, management of facial paralysis, facial skin cancer, facial reconstruction, and surgery of the aging face.Note: The faculty for this program had full editorial control of the content.The following program was funded by Sanofi.Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

Please visit answersincme.com/PQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in squamous cell carcinoma of the head and neck (SCCHN) discusses the clinical potential of antagonists of inhibitor of apoptosis proteins (IAPs) for unresected, locally advanced SCCHN. Upon completion of this activity, participants should be better able to: Identify the rationale for investigating the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN); Discuss the latest efficacy and safety data for emerging IAP antagonists for the treatment of unresected LA SCCHN; and Outline clinical considerations for future use of IAP antagonists in unresected LA SCCHN.

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

You have a patient referred to you for a history of anal dysplasia and found to have an anal lesion on colonoscopy. How do you evaluate this? What are the risk factors? How will you perform surveillance afterwards? Does everyone need HRA? Tune in to find out! Join Drs. Peter Marcello, Jonathan Abelson, Tess Aulet and special guest Dr. Lisa Breen as they discuss high yield papers discussing Anal Dysplasia.  Learning Objectives 1. Describe the different types of anal dysplasia and pathologic categorization 2. Describe high risk populations for development of anal squamous cell cancer 3. Discuss the different options and recommendations for surveillance and treatment of anal dysplasia Video Link: https://www.youtube.com/watch?v=YdOjV1Gcqvk **Introducing Behind the Knife's Trauma Surgery Video Atlas - https://app.behindtheknife.org/premium/trauma-surgery-video-atlas/show-content The Trauma Surgery Video Atlas contains 24 scenarios that include never-before-seen high-definition operative footage, rich, original illustrations, and practical, easy-to-read pearls that will help you dominate the most difficult trauma scenarios. ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9*** Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out more recent episodes here: https://app.behindtheknife.org/listen

The saying "saving your skin" takes on extra meaning when you are outdoors. Living a "sun and fun" lifestyle can come with a price -- the sun's damaging UV rays and the risk of skin cancer. Hopefully, you practice safety by using sunscreens, hats and clothing to mitigate those harmful rays. Some people forget that sun damage and skin cancer can be synonymous. As spring and summer approach, how do we avoid skin cancer? And if it leaves a concerning spot on the skin, what do we do next? Host: Jonathan Fialkow, M.D., Chief Medical Officer at Baptist Health who oversees Population Health, Primary Care, Cardiology, Endocrinology and other Medical Specialties Guest: Michael Raish, M.D., Mohs Micrographic Surgeon and Dermatologist, Baptist Health Miami Cancer Institute 

BUFFALO, NY- January 31, 2024 – A new #research paper was #published on the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 2, entitled, “Prognostic significance of senescence-related tumor microenvironment genes in head and neck squamous cell carcinoma.” The impact of the senescence related microenvironment on cancer prognosis and therapeutic response remains poorly understood. In this new study, researchers Young Chan Lee, Yonghyun Nam, Minjeong Kim, Su Il Kim, Jung-Woo Lee, Young-Gyu Eun, and Dokyoon Kim from Kyung Hee University, Kyung Hee University Hospital at Gangdong, and the University of Pennsylvania investigated the prognostic significance of senescence related tumor microenvironment genes (PSTGs) and their potential implications for immunotherapy response. Using the Cancer Genome Atlas- head and neck squamous cell carcinoma (HNSC) data, the researchers identified two subtypes based on the expression of PSTGs, acquired from tumor-associated senescence genes, tumor microenvironment (TME)-related genes, and immune-related genes, using consensus clustering. Using the LASSO, they constructed a risk model consisting of senescence related TME core genes (STCGs). The two subtypes exhibited significant differences in prognosis, genetic alterations, methylation patterns, and enriched pathways, and immune infiltration. “Our risk model stratified patients into high-risk and low-risk groups and validated in independent cohorts.” The high-risk group showed poorer prognosis and immune inactivation, suggesting reduced responsiveness to immunotherapy. Additionally, the team observed a significant enrichment of STCGs in stromal cells using single-cell RNA transcriptome data. Their findings highlight the importance of the senescence related TME in HNSC prognosis and response to immunotherapy. “This study contributes to a deeper understanding of the complex interplay between senescence and the TME, with potential implications for precision medicine and personalized treatment approaches in HNSC.” DOI - https://doi.org/10.18632/aging.205346 Corresponding authors - Young-Gyu Eun - ygeun@khu.ac.kr, and Dokyoon Kim - dokyoon.kim@pennmedicine.upenn.edu Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205346 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cellular senescence, head and neck cancer, immunotherapy, microenvironment, single cell About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Join us as we go through the JEADV Editor's Picks of January 2024: (1) A Treatment with Antineoplastic Potential in Squamous Cell Carcinoma (2) Describing Penile Cancer Carcinogenesis and The Role of HPV (3) Sensitive Skin may be Neuropathic in Nature (4) Urgency of Optimal Imaging in Toxic Epidermal Necrolysis   Read the Editor's Picks here: https://onlinelibrary.wiley.com/doi/10.1111/jdv.19624   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses the role of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

SHOW NOTES 0:55 - Contextual introduction for this episode's unique features 3:20 – Sample DJ clips 4:15 – Guest introduction 5:05 – Cancer, voice change, a long stint behind the high school football stadium game night microphone 6:00 – Rick starts his three-decades of announcing Friday night home games 7:55 – Son Rowdy follows Dad Rick at the football field 8:45 – Family members want to hear the players' names 10:30 – Daughter Grace, a performance from the (very) early years 12:00 – David (Reynolds) stands in for Brad Pitt 13:25 – Wife Margaret makes a huge difference in the community 15:55 – The story behind Be Nice to Grace Day 21:05 – Jeanne Burr (and Walter Hooper) as a catalyst for Rick on the air for the first time (at age 17) 24:45 – Listening to Chicago's AM station WLS 27:00 – John Records Landecker 30:00 – A lesson learned about making others feel important 32:24 – Interviewing Garth Brooks 33:40 – The first time cancer rears its head 39:30 – Focused radiation, bolted to the table, and a special mask 43:10 – Jimmy Buffet embedded in a family tradition 44:40 – Cancer reappears – in a new location 46:00 – Friend Amy's powerful question 46:40 – God's gameplan for Rick 49:45 – Lydia, a face from the past, and a new connection for the future 52:35 – High school reunion delays 54:10 – Living in a small town, great friends, great community 58:00 – Sharing one's story to give others hope 59:40 – A lesson Rick wants us to hear 1:04:40 – One of many similar stories of good fortune – Running out of gas on I-75 North 1:07:00 – A mini-facelift's role in the past twenty years of Rick's life 1:07:50 – The most recent doctor's visit and current prognosis 1:09:40 – The unexpected result of Rick losing his voice  LINKS:Instagram: @therickontheradioJohn Records LandeckerEmory Proton CenterRowdy Zeisig, the new Dalton High School football announcerJeanne BurrDunaway Drug StoreBeaulieu's beginningJimmy Buffet's 'Twas the Night Before ChristmasMusic for Lead. Learn. Change. is Sweet Adrenaline by Delicate BeatsPodcast cover art is a view from Brunnkogel (mountaintop) over the mountains of the Salzkammergut in Austria, courtesy of photographer Simon Berger, published on www.unsplash.com.Professional Association of Georgia EducatorsDavid's LinkedIn page 

In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from September 18, 2023 – September 22, 2023.  Please check back every Monday morning so that you can stay up to date.  Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See more details summaries and links to prescribing information at nascentmc.com/podcast Here are the highlights: Jardiance (empagliflozin) for CKD  The FDA has approved Jardiance, an SGLT2 inhibitor, for patients with end-stage kidney disease, speciifically to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. The approval is based on the EMPA-KIDNEY phase 3 trial, demonstrating a significant reduction in kidney disease progression and cardiovascular death compared to a placebo.  Welireg (belzutifan) for Advanced Renal Cell Carcinoma The FDA granted Priority Review for Merck's Welireg for advanced renal cell carcinoma post other treatments. Welireg, a HIF-2α inhibitor, is being evaluated in the LITESPARK-005 trial, where it was compared with everolimus for advanced RCC treatment post PD-1/L1 or VEGF-TKI therapies. Tevimbra (tislelizumab) for Esophageal Squamous Cell Carcinoma The FDA is reviewing an application for Tevimbra for treating advanced or metastatic esophageal squamous cell carcinoma. Supported by the phase 3 RATIONALE 306 study, the drug improves overall survival rates when combined with chemotherapy in these patients. Neffy Epinephrine Nasal Spray The FDA rejected the approval of Neffy, a needle-free nasal spray for allergic reactions. Despite a positive Advisory Committee vote, the FDA demands further testing. ARS Pharmaceuticals plans to re-submit its application and appeal the decision in 2024.  Intro and outro music Garden Of Love by Pk jazz Collective

This is a recap of the top 10 posts on Hacker News on July 22nd, 2023.This podcast was generated by wondercraft.ai(00:38): I am dying of squamous cell carcinoma, and potential treatments are out of reachOriginal post: https://news.ycombinator.com/item?id=36827438&utm_source=wondercraft_ai(02:27): Plane – Open-source Jira alternativeOriginal post: https://news.ycombinator.com/item?id=36824450&utm_source=wondercraft_ai(04:13): Shopify employee breaks NDA to reveal firm replacing laid off workers with AIOriginal post: https://news.ycombinator.com/item?id=36828409&utm_source=wondercraft_ai(06:00): FBI improperly used 702 surveillance powers on US senatorOriginal post: https://news.ycombinator.com/item?id=36822654&utm_source=wondercraft_ai(07:45): Putting the “You” in CPUOriginal post: https://news.ycombinator.com/item?id=36823605&utm_source=wondercraft_ai(09:13): Compromised Microsoft key: More impactful than we thoughtOriginal post: https://news.ycombinator.com/item?id=36823007&utm_source=wondercraft_ai(11:18): A Caltech Nobel laureate celebrates his 100th birthday, then gets back to workOriginal post: https://news.ycombinator.com/item?id=36828811&utm_source=wondercraft_ai(13:07): AWS networking concepts in a diagramOriginal post: https://news.ycombinator.com/item?id=36823516&utm_source=wondercraft_ai(14:53): Important Coding HabitsOriginal post: https://news.ycombinator.com/item?id=36826755&utm_source=wondercraft_ai(16:38): What we talk about when we talk about system designOriginal post: https://news.ycombinator.com/item?id=36823375&utm_source=wondercraft_aiThis is a third-party project, independent from HN and YC. Text and audio generated using AI, by wondercraft.ai. Create your own studio quality podcast with text as the only input in seconds at app.wondercraft.ai. Issues or feedback? We'd love to hear from you: team@wondercraft.ai

Please visit answersincme.com/KDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the use of neoadjuvant immunotherapies in the treatment of surgically resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the rationale for using neoadjuvant immunotherapies for patients with surgically resectable CSCC; Review the latest evidence on the efficacy and safety of emerging neoadjuvant immunotherapies for patients with surgically resectable CSCC; and Outline clinical strategies to optimize the therapeutic management of surgically resectable CSCC for patients who would be appropriate candidates for neoadjuvant immunotherapies.

Please visit answersincme.com/EEF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck squamous cell carcinoma (HNSCC) discusses the clinical significance of emerging antagonists of inhibitors of apoptosis proteins (IAPs) for patients with HNSCC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for emerging antagonists of IAPs for patients with resectable and unresectable locally advanced (LA) HNSCC; Review the clinical significance of emerging antagonists of IAPs in the treatment of unresectable LA HNSCC, based on the latest efficacy and safety data; and Outline strategies for how antagonists of IAPs may fit into future treatment algorithms for patients with resectable and unresectable LA HNSCC, as they become available.

Mga Tanda ng Kaniyang Pagbabalik

CME credits: 0.25 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-the-treatment-of-locally-advanced-squamous-cell-carcinoma-of-head-and-neck-enhancing-antitumor-activity-through-inhibitor-of-apoptosis-protein-antagonism/14129/ There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.

A new research paper was published in Oncotarget's Volume 13 on October 20, 2022, entitled, “Nectin-4 is widely expressed in head and neck squamous cell carcinoma.” Nectin-4 has been successfully established as a target molecule in locally advanced and metastatic bladder cancer. An antibody-drug conjugate (enfortumab-vedotin) directed against nectin-4 has shown marked tumor remission rates in this tumor type, which is known for high expression rates of nectin-4. As head and neck cancer and urothelial carcinomas share morphological and molecular similarities, researchers Christine Sanders, Jan-Frederic Lau, Dimo Dietrich, Sebastian Strieth, Peter Brossart, and Glen Kristiansen from University Medical Center Bonn and University Hospital Bonn aimed to evaluate Nectin-4 expression in head and neck squamous cell carcinoma (HNSCC). A previously described and clinically characterized cohort of HNSCC (n = 159) was analyzed by immunohistochemistry for Nectin-4 expression. The expression data was correlated to clinico-pathological parameters including patient outcome. Nectin-4 was found in 86.2% of HNSCC, with medium/high expression seen in 32.7% of cases. Non smokers and p16 positive HNSCC showed a higher expression of Nectin-4 (p < 0.005). There was no correlation of Nectin-4 with grading or tumor stage. Nectin-4 positive tumors showed significantly better survival (log rank p = 0.006). “Similar to urothelial carcinoma, Nectin-4 is found in the majority of HNSCC, which clearly warrants further studies to clarify if HNSCC also respond to targeted therapy with enfortumab-vedotin. Moreover, expression of Nectin-4 is associated with HPV infection and may serve as a prognostic marker in HNSCC.” DOI: https://doi.org/10.18632/oncotarget.28299 Correspondence to: Glen Kristiansen - Email: glen.kristiansen@ukbonn.de Video - https://www.youtube.com/watch?v=tDY21YpFsKc Keywords: Nectin-4, enfortumab-vedotin, HNSCC, p16 About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com Oncotarget Journal Office 6666 East Quaker Str., Suite 1A Orchard Park, NY 14127 Phone: 1-800-922-0957 (option 2)

In September 2022, the U.S. Food and Drug Administration (FDA) put out a safety alert about reports of squamous cell carcinoma and other lymphomas in the scar tissue that forms around breast implants. Listen to the episode to hear Dr. Wojciechowski explain: what squamous cell carcinoma is and how it's different from anaplastic large-cell lymphoma  what he thinks about squamous cell carcinomas being found in the scar tissue around both textured and smooth breast implants the rarity of squamous cell carcinoma in implant scar tissue, how he's talking to patients about it, and what women should look for

When Eric Rodriguez was 15 years old, he was diagnosed with an Optic Glioma. A few years later, he developed lesions in his mouth which turned into Squamous Cell Carcinoma, a cancer that was found in his head and neck. Eric was able to go into remission for 13 years, but then his cancer returned and he passed away on December 29th of 2021. Eric's mother Anita will talk about the life that Eric led , the impact that he had on others,  and the legacy that he left behind. She will also discuss the Boston Marathon Jimmy Fund Walk, which is the largest participatory event that the Jimmy Fund sponsors.  This event will take place this Sunday October 2nd and Anita, family members, and friends, will be walking together as members of BEYOND CANCER to raise money in honor and memory of Eric.

Lung Cancer Histology and Staging*Workup for a nodule that is concerning: **Ensure there is a dedicated CT scan of the chest to evaluate **Try to obtain old imaging; the rate of change is important **Can get PET, but even if a lesion if not FDG-avid, but growing quickly we should consider biopsy anyway**Referral to pulmonary medicine, who can assist with biopsy and also regional lymph node evaluation (important – more below)**PFTs are often ordered because it provides information about lung function in anticipation of possible surgery for treatment Lung Cancer Histology: *Non-small cell lung cancer (NSCLC)**Umbrella term for a variety of cancers**Increased risk in smokers**More common types: ***Adenocarcinoma (~50% of all lung cancers)****Most common overall; cancer of the mucus producing cells****IHC: TTF-1, NapsinA, CK7 positive***Squamous Cell Carcinoma (22.7%)****More often seen in patients with a smoking history ****IHC: p63 positive and cytokeratin pearls***Remaining ~15% are the other types of lung cancer / mixed histologies**Small cell lung cancer (SCLC)***Neuroendocrine tumor with very different pathology***Much more aggressive than NSCLC***Oncologic emergency***IHC: Chromogranin and synaptophysin positive IHC pearls: TTF-1 usually means lung cancer (but can be negative in squamous cell lung cancer). This will be important in the future (we promise :])*Staging for NSCLC:**Nodal evaluation: lymph node evaluation is part of the workup for NSCLC**Single digit = central/mediastinal nodes (higher risk)**Double digit = peripheral/hilar/intrapulmonary lymph nodes (lower risk)**“R” vs. “L” is direction *Pearl: Why is this important? If there is nodal involvement, systemic therapy is going to be necessary *Putting it all together: **T: Tumor size: T1-4**N: Nodal involvement***N0: no nodal involvement ***N1: Nodes closest to the primary tumor (double digits)****Ipsilateral peribronchial, hilar, intrapulmonary ***N2: Further away (single digit)****Ipsilateral mediastinal and/or subcarinal LN***N3: Contralateral any node or supraclavicular LN **M: Metastasis – in lung cancer, patients with certain patterns of metastatic disease are still curable! ***M0: no mets***M1a: Contralateral lobe, pleural effusion or pericardial effusion à these are generally still curable!***M1b: single site of metastatic disease à these are generally still curable!***M1c: multiple sites of metastatic disease à these are generally not curable*Staging for SCLC: **Limited stage - meaning it can fit in “one radiation field”**Extensive stage - does not fit in “one radiation field”*Once lung cancer is diagnosed:**Go to NCCN to learn the flow of ongoing management**Complete staging (if not already done):***CT C/A/P (don't necessarily need if a PET scan is done)***PET Scan***MRI brain à in general this is needed, but there are some exception to this (see NCCN)**Referral to pulmonary for nodal evaluationReferences: NCCN.orghttps://doi-org.proxy.library.vanderbilt.edu/10.1016/j.semcancer.2017.11.019-Article about IHC markers for lung cancer Please visit our website (TheFellowOnCall.com) for more information Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Getting a Squamous Cell Carcinoma diagnosis will, for some people, be one of the worst moments of their lives. As an oral surgeon, it's your responsibility to walk your patients through this moment, and the process that follows. In today's episode, Dr. Nicholas Callahan is here to share his thoughts on the kindest and most effective way to do this. We discuss everything from indicators of a potential Squamous Cell Carcinoma in the mouth and how to do a biopsy of an oral cavity lesion, to delivering a diagnosis to a patient, treating the cancer, and dealing with the potentially major life changes that take place after surgery. Nick also shares the importance of being open-minded as a dental student; you may be surprised by which areas of oral surgery make you feel fulfilled!Key Points From This Episode:Dr. Nicholas Callahan shares an overview of his background in oral surgery and his current areas of focus.Factors to take into consideration when choosing a fellowship or a residency training program.Reasons for the negative connotations associated with oral cavity cancer.Symptoms on the inside of the mouth which may signal Squamous Cell Carcinoma.Areas inside the mouth that are high risk for Squamous Cell Carcinoma. Why Nick worries more about painless ulcers than painful ones.Unlearning what you were taught at dental school about how to biopsy a potential cancer lesion.Why Nick prefers private practitioners to contact him directly when they have identified Squamous Cell Carcinoma in a patient.The initial screening process for a patient with Squamous Cell Carcinoma. Advice for delivering a Squamous Cell Carcinoma diagnosis to a patient.Steps to treating Squamous Cell Carcinoma.The survival rate for T4 cancers. Possible long-term effects of Squamous Cell Carcinoma surgery.The power of a positive mindset amongst cancer patients.Valuable advice for dental students: be open-minded and take advantage of every opportunity!A rapid-fire round with Nick.Links Mentioned in Today's Episode:Dr. Nicholas Callahan Email — ncall@uic.eduChicago Max Face on Instagram — https://www.instagram.com/chicagomaxface/?hl=en  The Road by Cormac McCarthy — https://www.amazon.com/Road-Cormac-McCarthy/dp/0307387895Ghostbusters — https://www.imdb.com/title/tt0087332/  Everyday Oral Surgery — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/?hl=en Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/ Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059

Ang Kahalagahan ng Pananalangin sa isang tagasunod

Listen to a soundcast of the May 27, 2022 FDA approvals of Opdivo (nivolumab) and Yervoy (nivolumab and ipilimumab) for advanced or metastatic esophageal squamous cell carcinoma, and Kymriah (tisagenlecleucel) for relapsed or refractory follicular lymphoma."”

It's a diagnosis nobody wants to hear: "You've got cancer."  Join Premier dermatologists as they explain the process of treating (and hopefully curing) a skin cancer.

In honor of Melanoma Awareness Month, Dr. Shaheer Khan, Assistant Professor of Medicine at Columbia University Irving Medical Center, shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligible for immunotherapy, and offers advice for members of the multidisciplinary cancer care team who are treating patients with this disease.

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long, MD (@long_brit), we look at two posts: recognizing skin cancer and new onset hyperglycemia. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

Interview with David Anthony Palma, MD, PhD, and Anthony C. Nichols, MD, authors of Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial Hosted by Jack West, MD.

Interview with David Anthony Palma, MD, PhD, and Anthony C. Nichols, MD, authors of Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial Hosted by Jack West, MD.

Are your patients tired of going under the knife? We don't blame them either. This week, join Drs. John Shen and Anna Nichols as they offer some non-invasive, cost-effective, and most importantly, non-surgical alternatives for your aging patients. Each Thursday, join Dr. Raja and Dr. Hadar, board certified dermatologists, as they share the latest evidence based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   John T. Shen, MD received his medical degree at Brown University and his undergraduate degree at the University of California, Los Angeles. After an internship at Brown University, Dr. Shen completed his dermatology training at Boston University. A member of the American Academy of Dermatology, Dr. Shen is an expert in non-invasive topical immunotherapy to treat skin cancers and precancers.   Anna Nichols, MD PhD is an Assistant Professor in the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine. Aside from directing the clinical trials unit and the High Risk Skin Cancer Clinic, Dr. Nichols is active in several promising and potentially groundbreaking research projects including preliminary work on the viral pathogenesis of squamous cell carcinoma. She regularly serves as the attending physician for an inpatient service where patients are treated for severe skin diseases.

On this week's episode Maddy and Shannon are talking to Matt Fumo, a spinal cord injury survivor and son of a Stage 4 Squamous Cell Carcinoma Survivor. To start the episode, Shannon and Maddy give a quick update and both have some exciting news to share! As they dive into the conversation with Matt, he discusses more details about how injury and how it happened, how medical professionals told him he would never walk again, growing up with a dad with cancer and where his dad is now in his cancer journey, and how him and his dad got even closer as they both had gone through life threatening medical occurrences. Matt also talks about his recovery after his accident and how seeing his dad fight and push through cancer, made him fight even harder for the ability to walk again. We also discuss the mind-body connection in relation to spinal cord injuries and cancer, and how it's so important. Matt is beyond inspiring, he fully recovered from his injury and is now training for a triathlon!! You can follow Matt on Instagram @mattfumo and keep up with us and our guests @canceractuallysuckspod. Follow Maddy on Instagram @cancersurvivor_nutritioncoach & Shannon @shancury!

Melanoma is the most serious form of skin cancer that starts in the deep layers of the skin in the cells that produce pigment. It is aggressive and potentially life-threatening. So, it's important that it be identified early when it is most treatable. In this podcast, Dr. Edward McCarron, a surgical oncologist and specialist in the treatment of the disease, talks about what melanoma is, how it is treated, and how to prevent it by knowing the ABCDEs of melanoma.Learn more: https://www.medstarhealth.org/services/melanoma-conditions

This week's episode covers everything you need to know about cutaneous squamous cell carcinoma.- presentation- risk factors- premalignant lesions- histopathology- workup and when to stage- grading- TNM staging- poor prognostic markers - management including topical treatments, surgery, radiotherapy, systemic treatments and nodal treatmentDisclaimerThe information in this podcast is intended as a revision aid for the purposes of the General Surgery Fellowship Exam.This information is not to be considered to include any recommendations or medical advice by the author or publisher or any other person. The listener should conduct and rely upon their own independent analysis of the information in this document.The author provides no guarantees or assurances in relation to any connection between the content of this podcast and the general surgical fellowship exam.  No responsibility or liability is accepted by the author in relation to the performance of any person in the exam.  This podcast is not a substitute for candidates undertaking their own preparations for the exam.To the maximum extent permitted by law, no responsibility or liability is accepted by the author or publisher or any other person as to the adequacy, accuracy, correctness, completeness or reasonableness of this information, including any statements or information provided by third parties and reproduced or referred to in this document. To the maximum extent permitted by law, no responsibility for any errors in or omissions from this document, whether arising out of negligence or otherwise, is accepted.The information contained in this podcast has not been independently verified.© Amanda Nikolic 2022

This episode covers head and neck cancer.Written notes can be found at https://zerotofinals.com/surgery/ent/headandneckcancer/ or in the ear, nose and throat section of the Zero to Finals surgery book.The audio in the episode was expertly edited by Harry Watchman.

In this episode, we review the high-yield topic of Squamous Cell Carcinoma from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial

Mga Tanda ng Kanyang ikalawang pag paparito.

It's been a while! I think we will call this the second season as it seems fitting as I head into another season of battling cancer. Devastated and angry are just two of the words that come to mind. But also with that come to surrender and faith. Thank you for being on the journey with me so far. Tag along as I fight cancer again. If you enjoyed this episode, make sure and give us a five star rating  and leave us a review on iTunes, Podcast Addict, Podchaser and Castbox. Sign up for the next DAC Bootcamp Follow me on Social Media:Amy on IGAmy on Facebook Resources:AmyLedin.comLean Bodies Consulting (LBC)LBC University 

In this episode, we review the high-yield topic of Squamous Cell Carcinoma (SCC) of the Skin from the Oncology section. --- Send in a voice message: https://anchor.fm/medbulletsstep1/message